| CAS NO: | 83919-23-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 521.43 |
|---|---|
| Formula | C27H30Cl2O6 |
| CAS No. | 83919-23-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 6 mg/mL (11.5 mM) |
| Water:<1 mg/mL | |
| Ethanol:<1 mg/mL | |
| Other info | Chemical Name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate InChi Key: WOFMFGQZHJDGCX-ZULDAHANSA-N InChi Code: InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1 SMILES Code: O=C(C1=CC=CO1)O[C@]2(C(CCl)=O)[C@H](C)C[C@@]3([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)=O |
| Synonyms | SCH-32088; Sch 32088; mometasone furoate cream (0.1); Sch-32088; Sch32088; |
| In Vitro | In vitro activity: Mometasone furoate efficiently suppresses production of cytokines including interleukin (IL)-4, IL-5, and interferon-gamma in anti-CD3-stimulated human CD4+ T cells. Mometasone furoate effectively inhibits the activation of Th cells including type 2 Th (Th2) in the draining LN, thus leading to the suppression of the IgE response. Kinase Assay: Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor. IC50 value: Target: glucocorticosteroid receptor Mometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma. |
|---|---|
| In Vivo | Mometasone causes a decrease in the instances of nasal rubbing and an inhibition of this response is observed during the treatment period in rats. Mometasone (3 mg/kg) inhibits the increased airway sensitivity to aerosolized methacholine at the highest dose tested in mice. Mometasone, given an hour after the last allergen challenge, dose-dependently inhibits the allergen-induced increase in Penh with about a 10-fold loss of potency when compared with the pre-challenge treatment schedule. Mometasone furoate (0.02%) and fluticasone propionate (0.1%) significantly inhibits the increase of antigen-induced nasal rubbing even 6 hours after topical application, indicating that both drugs have a long-lasting effect. Mometasone furoate dose-dependently inhibits the elevated eosinophil numbers in the bronchoalveolar lavage fluid and lung tissues of sensitized, ovalbumin challenged mice. Mometasone furoate (33 mg/kg) reduces the percentage of CD44+ T-helper cells (activated/memory cells) to the levels observed in non-sensitized, ovalbumin-challenged mice. |
| Animal model | ovalbumin-challenged mice |
| Formulation & Dosage | 3 mg/kg |
| References | Immunopharmacol Immunotoxicol. 2006;28(3):491-500; Eur J Pharmacol. 2005 Nov 7;524(1-3):155-8. |
m.cnreagent.com